Phase 2Status unknown

Study Exploring the Supportive Effect of Acarbose in Weight Management

A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability

Sponsor
Empros Pharma AB (Industry)
Enrollment
320 planned
Conditions
Overweight or Obesity
Interventions
EMP16-120/40; MR orlistat 120 mg; Conventional orlistat 120 mg,; EMP16-60/20; Placebo
Ages
adults, older adults
Registry
NCT05934110, EUCTR2022-003320-40

Full record on ClinicalTrials.gov

From the registry

This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat in its conventional dosage form and placebo.

Primary outcomes

  • Relative (%) change from baseline in body weight at week 26
  • Proportion of participants with ≥5% decrease in body weight at week 26 [Please note: This is an FDA required outcome, cannot use "change"]

History

  1. Study completion

  2. Last registry update

  3. Primary completion

  4. Registered

  5. Started